Aclarion, Inc. (ACON)
Aclarion, Inc. operates in the Medical - Healthcare Information Services industry of the Healthcare sector, headquartered in Broomfield, CA, US. The stock last traded at $2.29, up 0.44% on the session, giving a market capitalisation of $1.2M. On trailing twelve-month figures it carries a trailing P/E of -0.30, a net margin of -10978.5%. Its beta of 1.22 implies it has historically moved more than the broad market.
Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
Aclarion, Inc. is most often compared with the following Healthcare names: